Abstract
Tyrosine-protein phosphatase non-receptor type 12 (PTPN12) has been considered to be a tumor suppressor in human cancer, but its clinical and prognostic significance in non-small cell lung cancer (NSCLC) has not been well elucidated.A retrospective analysis of 215 patients with surgically resected NSCLCs from Sun Yat-Sen University Cancer Center between April 2002 and March 2005 was performed using immunohistochemistry and Western Blot to analyze PTPN12 expression. The association between PTPN12 expression and patient survival was investigated.Western Blots showed that the expression level of PTPN12 were higher in normal paracancerous lung tissues than in NSCLC tissues. High PTPN12 expression was less common in the presence than in the absence of visceral pleural invasion (p=0.038). Patients with PTPN12-high tumors had a longer disease-free survival (DFS) (P<0.001) and overall survival (OS) (p<0.001), especially for those with non-squamous cell carcinoma (non-SCC) (DFS, p<0.001; OS, p<0.001). Multivariate analysis confirmed that PTPN12 positivity was associated with increased survival duration (DFS, p<0.001; OS, p<0.001), independent of prognostic indicator.High PTPN12 expressive levels are associated with favorable survival duration in patients with NSCLC, especially those with non-SCC. Our study suggests that PTPN12 expression is a valuable prognostic biomarker for NSCLC patients.
Highlights
Lung cancer continue to be the most common causes of cancer death worldwide [1]
We observed that protein phosphatase non-receptor type 12 (PTPN12) expression correlated significantly with visceral pleural invasion and pTNM stage
In the histology subgroup analyses, we observed that the survival benefit of high-PTPN12 expression might be limited in non-squamous cell carcinoma (non-squamous cell carcinoma (SCC)) patients
Summary
Lung cancer continue to be the most common causes of cancer death worldwide [1]. Patients with non-small cell lung cancer (NSCLC), which account for 75%-80% of lung cancer cases, carry a 5-years survival rate of 10%15% for all stage. Many patients with the same pathological Tumor-Node-Metastasis (TNM). The American Joint Committee on Cancer Staging system (AJCC) may be not reliable to predict clinical outcomes. Studies conducted several years ago have suggested that cancer has been envisioned as a signaling disease [3]. A better understanding of the biochemical signaling molecules and genetic factors of NSCLC could provide valuable prognostic parameter, improve the prognoses of patients and provide therapies that are more appropriate [4,5,6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
